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Abstract: Mucosal surfaces play a central role in the pathogenesis of rheumatoid arthritis (RA). Several
risk factors, such as cigarette smoking, environmental pollution, and periodontitis interact with the
host at the mucosal level, triggering immune system activation. Moreover, the alteration of microbiota
homeostasis is gaining increased attention for its involvement in the disease pathogenesis, modulating
the immune cell response at a local and subsequently at a systemic level. Currently, the onset of the
clinical manifest arthritis is thought to be the last step of a series of pathogenic events lasting years.
The positivity for anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF), in absence
of symptoms, characterizes a preclinical phase of RA—namely systemic autoimmune phase- which is
at high risk for disease progression. Several immune abnormalities, such as local ACPA production,
increased T cell polarization towards a pro-inflammatory phenotype, and innate immune cell
activation can be documented in at-risk subjects. Many of these abnormalities are direct consequences
of the interaction between the environment and the host, which takes place at the mucosal level. The
purpose of this review is to describe the humoral and cellular immune abnormalities detected in
subjects at risk of RA, highlighting their origin from the mucosa–environment interaction.
Keywords: rheumatoid arthritis; mucosal immunity; ACPAs; microbiota; lung; periodontitis
1. Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease a↵ecting mainly the
joints. RA is characterized by synovial membrane inflammation, progressive cartilage damage, and
disability [1]. Pathogenesis of RA is complex and heterologous. Several genetic and environmental
factors concur to increase the risk of develop the disease. A series of pathological events occur before the
clinical onset of the disease, in a preclinical phase that can last many years. The pre-RA is characterized
by the emergence of autoantibodies in the absence of objective signs of joint inflammation [2]. Several
studies, performed on sample collected before the onset of RA, showed that anti-citrullinated peptides
antibodies (ACPAs) and rheumatoid factor (RF) are present up to 13 years before the clinical onset
of the disease [3]. The presence of RA-related autoantibodies predicts the clinical development of
the disease after a variable time lag, during which there is a progressive accumulation of multiple
specificities of the autoantibodies, results of an epitope spreading phenomenon [4]. ACPAs and RF
are considered hallmarks of seropositive RA and are biomarkers of a more erosive disease, greater
radiographic damage, and worst prognosis [5]. A number of other antibodies have been identified
in the serum of patients with RA, targeting post-translationally modified antigens as carbamylated
or acetylated proteins [6,7]. Similarly to ACPAs, antibody anti-carbamylated proteins (Anti-CarP)
have been detected years before the diagnosis and predict the evolution to RA [8,9]. While synovial
membrane is certainly a source of autoantibodies in established RA [10], most of the subjects in the
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preclinical phase of RA show no evidence of joint involvement at histologic examination, even though
their sera already contain autoantibodies [11]. The evidence of several immune abnormalities in
subjects at risk for RA without any joint involvement suggests that the pathogenic events leading to the
disease may occur outside the joints [12]. Many risk factors for RA are encountered at the mucosal level,
so mucosal immunity alterations are supposed to play a central role in the pathogenic events preceding
RA. Mucosae are the interface through which the host interacts with the environment. Virtually all the
mucosal sites are equipped with barrier mechanisms, both physical and immunological, to protect
the host from potentially harmful pathogens or toxins present in the environment. Apart from the
epithelial surface—which represents a mechanical barrier to the environment—at the mucosal level,
immunoglobulins, enzymes, complement, neutrophils, and macrophages act as a first line defense
against environmental hazards [13]. Moreover, most mucosal surfaces possess a resident lymphatic
tissue, the mucosal-associated lymphatic tissue (MALT), which can directly interact with antigens and
develop immune responses. At the mucosal level, immunological events such as the development
of antigen-specific T cells, B cell expansion, class switching, and local immunoglobulin production
contribute to the development of the in situ immune response, which, through the migration of the
antigen-carrying dendritic cells to the local lymph nodes, can induce a systemic immune response [14].
Besides the defensive function, the mucosal immune system also represents a site of interaction
with commensal and symbiotic microorganisms, which together with the pathogenic microorganism
represent the microbiota [15]. The variety of the microbiota composition shapes the immune response
at the mucosal level, influencing both the innate and the adaptive immunity [16]. A perturbation of
the normal microbiota homeostasis, through a reduction of protective bacterial species e/o an increase
of potential pathogenic bacteria—i.e., the dysbiosis—has been implicated in several inflammatory
and autoimmune conditions, including RA [17–19]. The purpose of this review is to explore the link
between the immune abnormalities present in subjects at risk for RA and the possible influences of
environmental factors at the mucosal level.
A Multistep Model of RA Development and Genetic Predisposition
The current model of RA pathogenesis involves a multistep process, lasting decades before
the clinical onset of the disease. The interplay between genetic and environmental factors predates
the systemic immune alteration and contributes to the break of immunologic tolerance. Genetic
predisposition is linked to more than 100 HLA and non HLA susceptibility loci, and overall 2/3 of the
risk for the disease development is genetically determined [20]. The strongest genetic risk factor for RA
lies within the human leucocyte antigen (HLA) class II region and encodes the HLA-DRB1 molecule.
In particular, alleles encoding for the shared epitope (SE) are a strong risk factor for seropositive
RA development. SE represents a motif of five amino acid residues in the binding groove of the
DR chain, which can a↵ect the antigen presentation to T cells [21,22]. Several non HLA loci have
been associated with RA susceptibility, including PTPN22, CTLA4, and loci for cytokines, cytokines
receptors, and signal transduction mediators [20]. In genetically susceptible individuals, the e↵ect of
several environmental factors may influence the development of systemic autoimmunity, such as the
appearance of autoantibodies and the increase of circulating levels of cytokines and chemokines, in the
absence of clinical manifestation [2]. Over time, the predisposed subjects may develop inflammatory
arthralgia without a clinical arthritis. Patients with inflammatory arthralgia, positive for RF and
ACPAs, have a high risk—nearly 30% in one year—of imminent arthritis development [23]. Recently,
the European League Against Rheumatism (EULAR) released a definition of arthralgia suspicious
for progression to RA, providing a set of clinical parameters to identify these patients for research
purposes [24]. Although some patients with inflammatory arthralgia may show a subclinical synovitis,
most of the patients do not present any sign of subclinical joint inflammation, suggesting that
immune abnormalities might start outside the joint [25–27]. Abnormalities in the humoral and cellular
components of innate and adaptive immunity are detectable in the systemic autoimmune phase of RA
(synthetized in Figure 1).
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2. Humoral Immunity Abnormalities in At-Risk Subjects
2.1. The Lung as a Site of ACPA Production
As mentioned above, the autoantibodies associated with RA can be detected years before the
onset of the apparent disease. The lung is the most investigated site of autoimmunity generation,
although the exact pathogenic interaction between gene and environment is still unclear. The strong
association between cigarette smoke and ACPAs in subjects positive for SE-HLA-DRB1 alleles supports
the mucosal origin of anti-citrulline response. SE-containing class II MHC molecules have a high
a nity for citrullinated peptides, with consequent T cell presentation and autoimmune response to
citrullinated self-antigens [28]. However, other mechanisms could explain the association between SE
and RA. Recently, Fu et al. reported that SE can act as a calreticulin ligand and interact with the aryl
hydrocarbon receptor (AhR), determining Th17 di↵erentiation, osteoclast activation, and a worsening
of experimental arthritis [29]. Indeed, AhR is the mediator of the response to air pollutants and is
implicated in the pathogenesis of autoimmune disorders [30–32]. This intriguing mechanism could
also explain the association between SE-containing HLA-DRB1 alleles and autoimmune disorders
other than RA [33–36]. Besides the interaction with SE, cigarette smoke is a well-known inductor of
citrullination. The conversion of arginine into citrulline, catalyzed by the di↵erent isoforms of the
peptydil-arginine deiminase (PAD) enzymes, is a post-translational modification that is implicated in
several physiologic processes and occurs nonspecifically in inflammatory conditions [37]. Indeed, there
is an increased expression of citrullinated proteins and PAD2 in bronco-alveolar lavage (BAL) cells as
well as in mucosal tissue from bronchial biopsy of healthy smokers compared to nonsmokers [38]. Lung
mucosal exposure to air pollutants, including cigarette smoke, may be implicated in the generation
of other self-antigens and consequently in the development of other autoantibodies associated with
RA. Carbamylation is a proteins’ modification strictly associated with cigarette smoke exposure [39].
Carbamylated proteins have been demonstrated in the lung of patients a↵ected by chronic obstructive
pulmonary disease [39,40]. Besides tobacco smoke, several other respiratory inhalants have been
associated with post-translational modifications. Exposure to silica as well as other inorganic dusts,
such as in construction or electronic workers, have been associated with the risk of RA [41,42], acting
synergistically with cigarette smoke [43]. Similarly, exposure to organic dust, such as textile [44],
wood [45], and agriculture organic dust [46] has been associated with an increased risk for RA.
Although the molecular mechanisms explaining the association of dusts with RA are far from being
fully understood, several evidences link the exposition to inhalants to an increase in citrullination and to
the induction of an inflammatory state in the lung. Cadmium (Cd) is a common contaminant of several
organic and inorganic dusts, detectable also in cigarette smoke. Hutchinson et al. demonstrated that
Cd nanoparticles induce the citrullination of cytokeratin in human bronchial epithelial cells through the
activation of calcium channels followed by calcium influx in cells, which leads to PAD activation [47].
Moreover, Cd exposure is associated with an increased expression of calreticulin, which, as stated
before, may explain the genetic risk associated with SE in inflammatory response predisposition [48].
The role of Cd in inducing citrullination may further explain the association between smoking, dust
exposure, and ACPA-positive RA [49]. The induction of protein citrullination is a characteristic
shared by nanoparticles of various origin—such as carbon or silicon nanoparticles—through an
increase of calcium levels and PAD activation, before the onset of any inflammatory change [50,51].
In mice exposed to organic dust, Poole et al. detected B cell activation, inducible bronchus associated
lymphoid tissue (iBALT) formation, inflammatory changes, and autoantibody production, as ACPAs
and anti-malondialdehyde-acetaldehyde antibodies [52]. Diesel exhaust particles, one of the most
important components of environment particulate emitted fromdiesel engines, can induce citrullination
on human epithelia bronchial cells [53]. This observation could partially explain the epidemiologic
association between the risk of RA and the high-density tra c pollution exposure [54].
The e↵ect of inhalationpollutant, especially cigarette smoke, inHLA-SEpositive subjects represents
an example of gene–environment interaction, which plays a relevant role in the induction of seropositive
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RA. In seronegative RA, by contrast, smoking exposure plays a negligible role [55]. This evidence may
thus suggest distinct etiologic origins of seronegative RA. Currently, T cell immune dysregulation seems
to play a major role in the pathogenesis of seronegative RA [56]. Abnormalities in other mucosal sites,
such as periodontal tissue and gut mucosa may play a more important role in these circumstances (see
Abnormal T Cell Polarization and T Cell Phenotypes). The role of lung abnormalities in seronegative
patients is currently not clear. A recent report failed to identify di↵erences in the prevalence of various
high-resolution chest tomography (HRCT) abnormalities between seropositive and seronegative RA
patients, suggesting a possible involvement of lung compartments regardless of serologic status [57].
Lung mucosal immunity can be influenced by environmental exposure to pollutants or by
change in microbiota homeostasis. Early RA patients show a lung dysbiosis characterized by a
reduced presence of several bacterial genera such as Actynomyces, Burkhordelia, and periodontopathic
taxa, including Prevotella and Porphyromonas, and an excess of Pseudonocardia. The presence of the
genus Prevotella seems to correlate with the serum levels of IgA-RF and with the number of ACPA
specificities, according to the role of this microorganism as a trigger of arthritis in both mouse models
and humans [58–60]. Moreover, Scher et al. showed a similar dysbiosis in RA patients and a control
group of patients with sarcoidosis, suggesting that inflammatory process per se may influence lung
microbiota composition [58]. Similarly, Demoruelle et al. reported a lower prevalence of Prevotella
genus and increased presence of Haemophilus and Streptococcus in subjects at risk of RA compared to
healthy controls [61].
Considering the influence of the various environmental factors on lungmucosa, it is not surprising
that the lung represents a site of autoantibody production. In fact, induced sputum of RA patients is
rich in ACPAs compared to the serum, and subjects at risk for RA without detectable ACPAs in the
serum can show positivity for ACPAs in the induced sputum [62]. Similar results have been observed
on BAL from newly diagnosed, untreated RA patients, showing a local enrichment of ACPAs compared
to serum; this latter study further suggests that the local production of autoantibodies may be an early
event during the pathogenesis of the disease [63]. These results parallel the evidence of structural
abnormalities in the lung of ACPA-positive subjects without RA as well as RA patients, further
suggesting a subclinical lung inflammation as a driver of the local production of autoantibodies [64].
Indeed, ACPA production has been demonstrated in several other non rheumatologic conditions
characterized by lung mucosal inflammation, as bronchiectasis or cystic fibrosis [65]. Inflammatory
changes in airways and alveoli are strictly associated with seropositive RA. Reynisdottir et al. reported
an almost double prevalence of parenchymal abnormalities in HRCT in ACPA-positive RA compared
to seronegative RA and healthy controls [63]. Moreover, Reynisdottir et al. demonstrated bronchial
biopsy inflammation characterized by ectopic lymphoid structures composed by (iBALT) with germinal
centers and plasmacells in early ACPA-positive RA compared to seronegative RA [66]. Thus, iBALT
may represent the mucosal structure responsible for the production of autoantibodies. Rangel-Moreno
et al. detected citrullinated proteins as well as an increased neutrophil extracellular trap (NET)
local release (see NETosis in Mucosal Inflammation and Citrullinated Antigen Generation) in iBALT,
suggesting a role of iBALT in ACPA production [67]. Similarly, subjects at risk of RA show increased
evidence of airway abnormalities in HRCT scans compared to healthy controls, mostly bronchial wall
thickening, bronchiectasis, centrilobular opacities, and air trapping, independently of a previous history
of smoking [68]. As reported above, the sputum of at-risk subjects may show positivity for ACPAs
even in the presence of serum negativity, suggesting a local production of autoantibodies predating
joint involvement [62]. Further studies demonstrated a temporal sequence in the ACPA specificity
development at the lung level. Sputum antibodies anti-citrullinated fibrinogen, anti-citrullinated
apolipoprotein E, and anti-citrullinated fibronectin are more prevalent in at-risk subjects compared to
those with established RA, suggesting that these antigens may be the earliest targets of antibodies
generated in the lung. Anti-citrullinated enolase antibodieswere the only subset showing a concordance
between serum and sputum in at-risk subjects, suggesting the appearance of these antibodies in the
transition from mucosal to systemic autoimmunity phase. At last, sputum antibodies anti-citrullinated
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histones were the most prevalent at the serum level in both at-risk subjects and RA patients compared
and healthy controls, suggesting that the appearance of these antibodies at the serum level may indicate
a transition to the clinical manifest disease. Moreover, the number of sputum antibody specificities
increases from the preclinical phase to the clinical one, suggesting a possible lung epitope spreading
phenomenon—the same demonstrated at the serum level—which is concomitant to the transition to
the clinical manifest disease [69].
2.2. Periodontal and Gut Dysbiosis in the Humoral Autoimmunity
Although the inflammatory changes at the mucosal site as drivers of the local production of
autoantibodies have been mainly demonstrated at the lung level, other sites, such as periodontal
tissue and the gut, may represent sites of generation of autoimmunity and sources of autoantibodies.
Epidemiological studies demonstrated a strict relationship between chronic periodontitis (CP) and
RA. The two diseases share many risk factors such as genetic predisposition (including HLA-DRB1),
smoking, nutritional state, and low socioeconomic status [70,71]. Moreover, there is clinical evidence
of an association between the two conditions and the treatment of periodontitis ameliorates the RA
course [72]. Gingival tissues of patients with CP contain citrullinated proteins and express PAD2
and PAD4 [65]. ACPAs can be detected in gingival crevicular fluid and at the serum level in CP
patients [65,73]. In RA patients, serum levels of carbamylated proteins have been associated with
CP severity, suggesting that carbamylation may also occur in inflamed gingiva [74]. The severity of
CP is associated with the positivity in the gingival crevicular fluid of RA-associated autoantibodies,
even in non RA patients [75]. The severity of CP is also associated, in pre-RA subjects, to the
subsequent risk of arthritis development [76] and to the ACPA positivity in first-degree relatives
of patients with RA [77]. Therefore, CP may represent a triggering site, in genetically predisposed
subjects, to systemic autoimmunity development. Porphyromonas gingivalis is a causative periodontal
pathogen of CP. P. gingivalis is the only human pathogen known to express PAD and thus to be
able to citrullinate bacterial as well as host proteins, in particular fibrinogen and enolase. Bacterial
PAD, namely PPAD, shows also the unique feature of being able to citrullinate carboxy-terminal
arginines of various peptides, not shared by human PAD: this mechanism can potentially expand
the number of citrullinated epitopes that may be generated [78,79]. Other key virulence factors of
P. gingivalis are gingipains, cysteine-proteases that act synergistically to PPAD cleaving peptides for
subsequent citrullination, fimbriae, and lipopolysaccharide (LPS), which together activate a broad
range of immune receptors, inducing an inflammatory response [80,81]. Thus, P. gingivalis endows
both factors (inducing inflammation and providing PPAD) that can cause protein citrullination and
local ACPA production at the gum level. Moreover, P. gingivalis is able to induce neutrophils NETosis
(see NETosis in Mucosal Inflammation and Citrullinated Antigen Generation), which has been recently
demonstrated to be gingipains-dependent [82]. Mikuls et al. detected higher levels of antibodies
anti-P. gingivalis in RA patients compared to controls [83]. Similarly, a high prevalence of these
antibodies has been demonstrated in pre-RA, correlating with RA-associated autoantibodies and
to a high risk of RA; these evidences suggest that CP sustained by P. gingivalis may play a role in
the earliest phase of the disease [84]. According to the role of oral dysbiosis in the pathogenesis
of the CP [85], several pathogens have been linked to the disruption of local immune tolerance.
Aggregatibacter actinomycetemcomitans (Aa), is a Gram-negative bacteria agent of CP and aggressive
localized periodontitis [86]. Konig et al. demonstrated that crevicular fluid from CP patients contains
extensively citrullinated proteins, mirroring the joint citrullinome of RA [87]. Among all the other
CP-associated bacteria, Aa was the only one able to reproduce the pattern of citrullination detected in
the RA joint, through the production of leukotoxin A (Ltx-A) [87]. Ltx-A is a pore-forming toxin able
to increase the influx of calcium inside cells, to trigger hypercitrullination and to induce a neutrophil’s
death similar to NETosis. Patients with RA, especially HLA-SE positive patients, showed a high
prevalence of anti-Ltx-A antibodies, which were also associated with serum positivity of ACPAs and
RF [87]. This last finding was, however, not confirmed in a di↵erent cohort [88]. Moreover, little is
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known about the interactions between the various potential pathogens in promoting arthritis. Oral
inoculation with Aa or Fusobacterium nucleatum in a mouse model of collagen-induced arthritis resulted
in a faster arthritis development when compared to a mix of these two bacteria plus P. gingivalis. While
the reason for these di↵erent responses is not clear, Engstrom suggested that the di↵erent cytokine
milieu arising in response to the pathogenic microbiota can influence the progression to arthritis [89].
Citrullination has been found in the periodontal tissue of subjects with CP, even independently by
the presence of Aa or P. gingivalis in the gums, suggesting the importance of other bacterial species
as well as the host PAD activity [90]. A study on recent-onset RA showed a di↵erent oral microbiota
when compared to healthy controls, with a peculiar enrichment of the taxa Prevotella and Leptotrichia.
Unusual bacteria such as Anaeroglobus correlated to serum levels of ACPAs and RF [59]. More recently,
Chen et al. reported a di↵erent profile of oral microbiota of RA patients compared to osteoarthritis
patients and healthy subjects, with an enrichment of eight bacterial species, including Prevotella,
Streptococcus, Porphyromonas, Haemophilus, Rothia, Actinomyces, Granulicatella, Leptotrichia, Lautropia, and
Fusobacterium in RA patients. Conversely, healthy subjects were selectively enriched of the phylum
Firmicutes, Bacteriodetes, and Proteobacteria, which constitute the fundamental components of a
homeostatic microbiota and drive immune-tolerant responses (see Abnormal T Cell Polarization and
T Cell Phenotypes). The authors suggested that the abnormal oral microbiota profile could be a
useful diagnostic tool [91]. Interestingly, some bacterial species may be directly implicated in several
pathogenic aspects of the early RA [91]. For example, Prevotella shows the ability to remove galactose
terminal residues from glycosylated immunoglobulins, increasing the inflammatory potential [92] (see
Secretory Immunoglobulins and Aberrant Glycosylation).
Less is known about the role of gut mucosa in the pathogenesis of humoral abnormalities of
RA, although several studies have highlighted the relationship between gut dysbiosis and RA [93].
Recently, a proteomic analysis on gut mucosa showed the presence of several citrullinated proteins
both in RA patients and in healthy subjects. Among citrullinated proteins, 21 have been previously
identified at lung and joint levels, and three of them (actin, vimentin and fibrinogen) are known
ACPA targets. Colonic tissue from RA patients showed a relative abundance of citrullinated vimentin,
suggesting that colon mucosa may play a role in the breaking of tolerance in RA [94].
Several recent studies described microbiota changes in RA patients. The dysbiosis of early
RA is characterized by an increase of several species including Lactobacillus, Prevotella, Clostridium,
Gordonibacter, Eggerthella, Collinsella, Actinobacteria, and Lacnospiracheae and by a decrease of
Proteobacteria, Firmicutes, and Faecalibacterium [19,95–97]. Although gut dysbiosis is thought to
influence the pathogenesis of RA,mainly causing an imbalance in T cell polarization and innate immune
cell activation [98], some hypothesis link directly gut microbiota with the abnormal humoral response.
Prevotella sp. gained attention for its implication in dysbiosis in several mucosal sites (see above). Other
than driving a TH17 response and IL-6 and IL-23 production (see Abnormal T Cell Polarization and T
Cell Phenotypes), Prevotella could be implicated in the anti-citrullinated immune response through a
molecular mimicry mechanism. Recently, two new antigens, N-acetylglucosamine-6-sulfatase (GNS)
and filamin A (FLNA), have been identified as targets of T and B cell responses in about half of
RA patients [99]. GNS and FLNA presented by HLA-DR have a strong homology sequence with
Prevotella sulfatase and other bacterial epitopes, potentially linking the immune reaction against
the altered microbiota with the onset of a pathogenic systemic response, at least in a subgroup of
RA patients. Moreover, Pianta et al. reported GNS citrullination in vivo and a correlation between
antibody anti-citrullinated GNS and ACPA level [99]. Recently, an enrichment of intestinal Prevotella
sp. has been demonstrated in subjects at risk for RA, suggesting an early development of gut
dysbiosis [100]. Segmented filamentous bacteria (SFB) are commensal bacteria widely studied for their
immune-modulating properties. Flannigan et al. demonstrated that SFB colonization has a potent e↵ect
in inducing Th17 di↵erentiation, through the stimulation of IL-23 production in dendritic cells, which in
turn can activate type 3 innate lymphoid cells (ILC3) to secrete IL-22 [101] (see Innate Lymphoid Cells
May Link Microbiota Changes with T Cell Activation). The activation of IL-23/IL-22/IL-17 axis has been
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recently recognized as a key moment in the acquisition of the inflammatory activity of autoantibodies:
in preclinical RA, this axis modulates the glycosylation pattern [102] (see Secretory Immunoglobulins
and Aberrant Glycosylation). In collagen-induced arthritis, the depletion of gut microbiota after the
induction of the arthritis reduced disease severity, the serum levels of cytokines, and the pathogenicity
of anti-collagen antibodies through a change in the glycosylation pattern, but only slightly reduced the
antibody serum levels. On the contrary, an early depletion of the microbiota, before the induction of
the arthritis, was associated with a significant reduction of anti-collagen antibody serum levels and to
a reduced arthritis severity. Those e↵ects were also associated with a reduced intestinal production
of IL-22 and IL-17A [103]. Accordingly, the activation of the IL-23/IL-22/IL-17 axis mediated by gut
dysbiosis may take part in two di↵erent moments in the disease pathogenesis: after the induction of a
systemic anti-citrullinated response, increasing ACPA pathogenicity through changes in glycosylation
patterns, and before ACPA production, increasing the tendency to produce autoantibodies. Indeed, the
last e↵ect may be explained by the existence of a gut–lung crosstalk, in which gut dysbiosis contributes
to the development of inflammation and autoimmunity at the lung level. At the gut level, SFB
increases the polarization toward Th17, which can migrate to the lung, inducing iBALT formation and
autoantibody production in the pre-arthritic phase. Moreover, SFB selectively expand autoreactive Th17
cells, co-expressing SFB-specific T cell receptors (TCRs) in addition to their self-reactive TCRs, further
increasing the autoimmune process. These results highlight how perturbations in gut microbiota
may drive the development of an autoimmune humoral response in remote sites and may represent
the second hit in the transition to the clinically manifest disease [104]. However, data on the role of
dysbiosis as a trigger of the systemic autoimmune response are not conclusive. Further studies will
help in identifying the pathobiont species that may play a role in the various steps.
2.3. Secretory Immunoglobulins and Aberrant Glycosylation
The mucosal origin of the autoimmune reaction driving RA is suggested also by the relative
abundance of the IgA response in at-risk subjects. ACPAs IgA in serumand sputumhas been specifically
associated with the future development of RA in at-risk patients [62,105]. Moreover, IgA isotype RF
precedes the IgG response [106]. IgA is the most common isotype of immunoglobulin produced at the
mucosal level. They can exist in two subtypes, a monomeric circulating form and a dimeric secretory
form, though the latter can also be detected at a low concentration in the peripheral blood. The two
dimers of the secretory IgA are bound to a peptide, the secretory component, which is the result of
the cleavage of the receptor responsible for the lumen translocation of the Ig and can be detected
in the peripheral blood [107]. Roos et al. described a strong association between cigarette smoke
and secretory IgA-ACPAs, confirmed through the detection of the secretory component, suggesting
a possible airway mucosal origin of the anti-citrullinated response [108]. Accordingly, seropositive
subjects at risk for RA show an enrichment of circulating IgA plasmablasts, which share clonality with
IgG plasma cells and recognize several RA-related antigens [109]. More recently, the secretory form of
several autoantibodies—such as ACPAs, RF, and anti-CarP—have been reported to be increased in RA
patient serum, to have a high specificity for the disease, and surprisingly to consist mostly of IgM [110].
This observation may be linked to changes in the microbiota composition. In fact, besides IgA, IgM
can also be secreted at the mucosal level, where they play a key role in regulating the commensal
bacteria population and host–microbiota interactions. Recently, Magri et al. described a population of
memory IgM-B cells clonally related to IgM secreting plasma cells that inhabit gut mucosa [111]. These
B cell populations rapidly produce secretory IgM in response to microbiota changes. The secretory
IgM target several species of mucus-coated commensal bacteria, contributing together with IgA, to
select a single species of commensal bacteria and to increase the diversity and the homeostasis of the
microbiota itself [111]. Accordingly, the development of a gut dysbiosis may drive the development
of autoreactive B cells at the mucosal level, thus justifying the increase in the secretory IgM directed
against modified self-antigens.
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Another alteration in the humoral immunitydetectable before the onset of thedisease is the aberrant
glycosylation of the IgG molecules. Glycosylation is a post-translational modification that involves
two potential sites on the IgG, one on the Fc portion and the other involving the Fab hypervariable
region [112]. The glycosylation influences the biological properties of the IgG molecule, modulating
the inflammatory activity. In fact, a reduced terminal galactosylation increases the complement-fixing
activity of the IgG,while an increased fucosylation of the Fc region changes the a nity for the various Fc
receptors [113]. A reduced terminal galactosylation andan increased core fucosylation of the Fc fragment
have been reported in preclinical RA, and this modification precedes the onset of clinical arthritis. These
modifications are prevalent in IgG with ACPA specificity [114,115]. In subjects at risk for RA, a reduced
IgG-Fc terminal sialylation of ACPAs and a reduced sialyltransferase activity in plasmablasts have been
reported [102]. The absence of sialic acid residues on Fc increases IgG inflammatory activities through
an increased a nity for the Fc R [116,117]. Moreover, immune-complexes containing desialylated
ACPAs stimulate osteoclastogenesis both in vitro and in vivo, increasing the inflammatory bone loss in
RA patients, and the sialylation of the IgG abrogated the osteoclastogenic activity [118]. The reduced
sialylation of IgG depends from IL-23 activated Th17 cells. In fact, Th17 accumulate in germinal
centers in the asymptomatic phase and induce a downregulation of sialyltransferase in plasmablasts
and plasmacells through an IL-21- and IL-22-dependent mechanism [102]. This pro-inflammatory
reprogramming of Ig production could possibly drive the onset of the arthritis [102]. These previous
observations may connect the increases pro-inflammatory properties of ACPAs, mediated by changes
in the glycosylation pattern, with the imbalance of the T cell subtypes present in at-risk subjects. These
events can in part arise from mucosal immunity alteration.
3. Cellular and Innate Immune Abnormalities
3.1. Abnormal T Cell Polarization and T Cell Phenotypes
To date, there are limited studies about the T cell subsets of at-risk subjects. In ACPA-positive
subjects at risk for RA progression, a reduced frequency of naïve and regulatory T cells and an increased
population of atypical T cells, hyper-responsive to TCR stimuli—i.e., the inflammation-related T
cell—have been demonstrated in the peripheral blood [119,120]. The subset imbalance was predictive
of arthritis progression. The reduced regulatory activity may be an early event in the pathogenesis of
the disease. Reduced circulating and lymph nodes CD4+IL-10+ T cells have been reported in subjects
at risk for RA, with a subsequent increase in peripheral CD4+IL-17A+ T cells in close relationship with
the onset of the arthritis [121]. These results are in line with the observation of persistently increased
levels of IL-17 and CD4+IL-17A+ T cells in peripheral blood of early arthritis patients [122]. Overall,
this suggests a failure of regulatory activity in the asymptomatic phase, followed by the expansion of a
Th17 autoreactive population, which could mediate the inflammatory manifestations. On the contrary,
a previous study demonstrated an increase of circulating Th17 cells in at-risk patients and a decreased
frequency of these cells in the peripheral blood of RA patients. In the same study, the authors detected
an increased amount of Th17 in synovial tissue, indicating a selective homing of the Th17 cells in
the inflamed sites [123]. The apparent discrepancy between these results could be explained by the
timing of the subjects’ evaluation, considering that each individual may have di↵erences in the various
steps of disease progression. A multistep process in the Treg/Th17 balance seems to characterize the
preclinical phase of RA, but the precise event sequence still needs to be clarified. The IL-10/INF- 
ratio produced by peripheral blood mononuclear cells (PBMCs) in response to citrullinated antigens
show a progressive reduction from healthy subjects to preclinical RA and to RA; this highlights that
the failure in the Treg control of autoimmunity may be an important event in the transition from
preclinical RA to clinical arthritis [124]. Recently, Cheng et al. described a peculiar molecular signature
in the peripheral blood of a subgroup of at-risk subjects [125]. This phenotype has been linked to
specific C-to-T single-nucleotide polymorphisms (SNPs) located at position 1858 (C1858T) of the
human protein tyrosine phosphatase PTPN22 gene [125]. The role of PTPN22 as a risk locus for RA is
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well known, as it is the non HLA locus with the highest risk for RA, additive to the risk-related HLA
alleles [55,126,127]. In fact, PBMCs of at-risk subjects show an increased level of citrullinated histones,
an increased production of IL-2 and Th17 cytokines, and a reduced production of Th2 cytokines;
moreover, T lymphocytes have a peculiar hyperproliferative, hyperinflammatory, and hypoglycolytic
phenotype [127]. The attenuated phosphatase activity of PTPN22 strengthens the activation signals in
lymphocytes and reduces the expression of glycolytic enzymes, explaining the increased production
of IL-2 and the hypoglycolytic phenotype [127]. A reduced glycolysis in T cells is associated with a
depletion of intracellular ROS through an increased shift of substrates toward the pentose phosphate
pathway, which promotes the generation of NADPH and glutathione [128]. The lack of oxidant
signaling drives T cells through a hyperproliferative and hyperinflammatory phenotype, and restoring
the redox balance can suppress the pro-arthritogenic e↵ector function in RA [129]. Moreover, PTPN22
is a critical regulator of PAD4, performing an inhibitory e↵ect independent from its phosphatase
activity. Attenuation of the non phosphatase activity of PTPN22—inducing hypercitrullination—has
been related to the aberrant expression of Th17 and Th2 cytokines. In fact, the abnormal cytokines
profile could be normalized by a pan-PAD inhibitor, although the precise mechanism explaining how
hypercitrullination causes the aberrant expression of Th2 and Th17 cytokines is still unclear [129].
Alteration in mucosal microbiota plays a dominant role in shaping T cell polarization.
An homeostatic, healthy, and heterogeneous microbiota, through the production of short chain
fatty acids, induces the production of transforming growth factor-  in dendritic and epithelial cells,
promoting the di↵erentiation of T naïve cells in Treg [130]. On the contrary, several pathobionts
that dominate RA dysbiosis can alter the Th17/Treg balance. Prevotella copri induces dendritic
cell-mediated naïve T cell di↵erentiation through Th1 and Th17 [97,131]. A relative abundance of
Prevotella correlates with a reduction of probiont species (such as Bacterioides fragilis); Bacterioides fragilis
exerts an anti-inflammatory activity by increasing the Tregs through the interaction between Toll-like
receptor 2 (TLR2) and polysaccharide A [19,132]. As stated before, SFB induce a strong increase of
Th17 cells. Recently, a human gut commensal bacteria, Bifidobacterium adolescentis, replicated the same
e↵ects of SFB in mice, thus possibly playing a role in RA-associated dysbiosis [133]. Actinobacteria,
specifically Collinsella, are increased in the gut of RA patients and can trigger inflammation through
an enhanced IL-17 production from epithelial intestinal cells [134]. The influence of dysbiosis at
the gut level on T cell polarization are in part mediated from the activation of local innate immune
cells (see Innate Lymphoid Cells May Link Microbiota Changes with T Cell Activation). The loss
of the protective immunological function of the vermiform appendix may also contribute to the
imbalance of the bacterial species, to the dysbiosis persistence, and to the pro-inflammatory state. The
vermiform appendix represents a highly immunologic organ particularly rich of Treg, contributing to
the peripheral tolerance. This tolerogenic function may be related to the particular local microbiota
composition of the vermiform appendix. In fact, themost abundant bacteria phyla found in themucosal
biofilm of the vermiform appendix are Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria, largely
confirming the role of the appendix as a commensal bacteria reservoir. Consequently, acting as a
probiont species niche, the appendix may contribute to microbiota homeostasis re-inoculating a large
bowel of commensal bacterial species after intestinal perturbations or infections, following diarrheal
clearance [135]. Epidemiological studies reported an association between the increased risk of RA and
a previous appendicectomy that may be partially explained by the loss of the appendix contribution to
the microbiota homeostasis [136,137]. However, other studies failed to confirm this association, and
more investigations are needed to understand the role of the appendix in the microbiota homeostasis
maintaining and in RA pathogenesis [138,139].
Periodontitis is also associated with a strong di↵erentiation in terms of Th17. Oral microbiota
influences the accumulation of Th17, the conversion of Treg in Th17, and local and systemic
pro-inflammatory cytokine production [140]. P. gingivalis contributes to Th17 imbalance, promoting
their di↵erentiation through gingipains activity, increasing the local levels of Th17 andpro-inflammatory
cytokine production [140].
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3.2. Innate Lymphoid Cells May Link Microbiota Changes with T Cell Activation
Innate lymphoid cells (ILCs) are a population of lymphoid origin, which lack of somatically
rearranged antigen receptors. Three main subtypes of ILCs are involved in shaping the
immune response. ILC1 and ILC3 are mainly inflammatory subsets, producing INF-  and IL-17,
respectively [141]. An increased frequency of ILC1 is present at the lymph node level in RA patients as
well as in at-risk subjects, while ILC3 is increased in patients with early RA [142]. Although the precise
dynamics of these changes remain unclear, the increased prevalence of pro-inflammatory subsets of ILC
in early phases of the disease suggests a role of these populations in the imbalance toward Th17 and
Th1 di↵erentiation, which may originate at the mucosal level. Indeed, ILC3 are a key cell type in the
regulation of microbiota composition. These cells can directly respond to several microbial components
through TLR2, -3, and -9. AhR is a key regulator of these cells, sensing the tryptophan catabolite
indole-3-carbinol produced by various bacterial species—notably Lactobacillus—and inducing IL-22
production. Moreover, ILC3 also responds indirectly to several cytokines, such as IL-23 and IL-1 ,
produced by mononuclear phagocytes under the control of microbial signals. The main products of
ILC3—i.e., granulocyte-macrophage colony stimulating factor (GM-CSF), IL-17, TNF, and IL-22—aside
from controlling the epithelial barrier integrity and the production of epithelial antimicrobial peptides,
enhance Th17 activity through the production of serum amyloid A [143,144]. The microbiota-induced
activation of ILC3, together with the stimulation of other resident innate immune cells, such as dendritic
cells and macrophages, directly influences the locally produced cytokines milieu and drives Th17
di↵erentiation. Several pro-inflammatory cytokines, such as IL-6, IL-1 , and IL-23, stimulate the
di↵erentiation of naïve T lymphocytes through Th17 phenotypes, which in turn may increase the
inflammatory response at the systemic level, worsening or triggering joint inflammation [145] (see
Figure 1). Accordingly, Schirmer et al. demonstrated how systemic inflammatory cytokine production
is influenced by microbiota composition. Using metagenomic sequencing to identify the taxonomic
profile of stool samples, the authors demonstrated that microbiota composition directly correlates with
cytokines produced by stimulated PBMC, therefore influencing the systemic cytokines response [146].
3.3. NETosis in Mucosal Inflammation and Citrullinated Antigen Generation
Neutrophils are involved in the mucosal pathogenesis of RA. These cells represent the first-line
defense against pathogens, migrating to inflammatory sites under the e↵ect of chemotactic stimuli and
providing antimicrobial activity through several mechanisms such as phagocytosis, degranulation,
and oxidative bursts [147,148]. A relevant defense mechanism involved in RA pathogenesis is the
neutrophil death by NETosis. Neutrophil extracellular traps (NETs) are strands of nucleic acids
bound to nuclear, cytoplasmic, and granular proteins extruded in the extracellular space induced by
several microbial and non microbial danger signals [149]. The NETosis process requires the activity
of PAD4, which, citrullinating the histones, promotes chromatin decondensation [150]. Thus, the
extracellular release of NET represents a source of citrullinated autoantingens, such as histones, and
other proteins, such as vimentin [151]. Citrullinated molecules released during NETosis are targets of
ACPAs in RA; ACPAs in turn can stimulate NETosis [151]. Antibodies directed against citrullinated
histones are present in up to 67% of patients with established RA and up to 48% in early RA [152].
These antibodies are also present in a subgroup of at-risk subjects, and their serum levels and their
presence increase steadily over time before the onset of joint symptoms [153]. Citrullinated histones
and their specific autoantibodies may appear early in the pathogenesis of the diseases. In fact, Chang
et al. demonstrated that neutrophils from a group of RA patients show a heightened propensity for
spontaneous NETosis and hypercitrullination. This phenotype is associated with C1858T SNPs of the
PTPN22 gene [125]. As mentioned above, non phosphatase activity of PTPN22 is a critical regulator of
PAD4. The increased activity of PAD4 leads to higher citrullination and spontaneous NETosis, which,
in the presence of susceptible HLA alleles, may induce the development of ACPAs [125]. Considering
that the increased propensity to NETosis related to PTPN22 C1858T SNP has been associated with
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several autoimmune diseases, the specific role of PAD activities in the regulation of immune cells in
RA is yet to be defined [149].
Increased neutrophil NETosis has been identified in several mucosal sites potentially implicated
in RA pathogenesis. In periodontitis, there is a local production of citrullinated proteins and ACPAs as
well as increased NETosis [154]. Causative periodontitis agents strongly induce NETosis. Gingipains
produced by P. gingivalis are potent activators of NET release, through the proteolytic activation
of the PAR-2 receptor. NET induced by P. gingivalis lack bactericidal activity for the subsequent
proteolytic inactivation of the NET proteins by gingipains. These mechanisms turn NET in favor
of P. gingivalis, generating an environment rich in peptides and growth factors released by dying
neutrophils that sustain the proliferation of pathogens [82]. Ltx-A produced by Aa is another potent
inducer of leucotoxic hypercitrullination, a toxin-mediated cell death similar to NETosis. Thus, the
generation of citrullinated proteins may explain the correlation between anti-Ltx-A antibodies and
serum ACPAs detected in RA patients [87,155]. NETs are abundant in the gingival crevicular fluid of
patients with CP [156]. Moreover, levels of circulating NET correlate with periodontitis severity in RA
patients [74].
A number of evidences support the role of NETosis in the local inflammation of several lung
diseases [157]. Moreover, cigarette smoke triggers NETosis directly or as an e↵ect of nicotine, through
the activation of acetylcholine receptors, and consequently induces the activation of dendritic cells and
Th17 polarization [158,159]. Nicotine administration increases NETosis and worsens inflammation
in arthritis mouse models [159]. Subjects at risk for RA show an increase of NET in the sputum,
parallel with the sputum ACPA level, suggesting a role for NETosis in local ACPA production [160].
A recent study showed a strong correlation between sputum NET and ACPAs directed towards
several citrullinated proteins, including proteins belonging to neutrophil cargo [69]. Besides generating
citrullinated peptides, NET may also be implicated in the development of iBALT. In fact, neutrophil
elastase contained in NET can convert IL-33 to its active form [161], triggering the release of IL-17F
by bronchial epithelial cells [162]. IL-17 trapped in NET then further recruits inflammatory cells
locally. IL-17 is a potent trigger for iBALT formation, acting together with the stroma-stimulating e↵ect
mediated by NETs [163]. Accordingly, under the influence of environmental factors, NETosis may be
another trigger of local immune activation in lung mucosa.
4. Conclusions
The understanding of molecular events occurring before the onset of RA has greatly improved.
The role of the mucosal abnormalities is relevant in the pathogenesis of the disease, with a determinant
contribution of each of the most implied mucosal sites. A series of pathogenic events may outline
a possible model of systemic autoimmune response development, in which oral and lung mucosa,
under the stimuli of environmental factors, represent sites of ACPA production while gut dysbiosis
increases the inflammatory state though increased Th17 polarization and IL-23/IL-17 axis activation
(Figure 2). ACPAs play a central role in the progression of the disease. The recent discovery of the
e↵ect of ACPAs on osteoclastogenesis and on peri-articular IL-8 production suggests a mechanism
explaining the transition from systemic autoimmunity to clinical symptoms, opening to the possibility
of therapeutic interventions to prevent the development of the disease [164]. However, targeting B
cells and consequently ACPA production through rituximab only delayed the diagnosis, instead of
preventing it [165]. The failure of the PRAIRI trial, aswell as other preventive strategies, suggests that, to
achieve an e↵ective and preventive strategy, we should focus on di↵erent pathogenic mechanisms [166].
Mucosal abnormalities are interesting targets for therapeutic strategies. Increasing the insights of the
molecular events at this level in at-risk subjects may o↵er new possibilities. For example, increasing
evidence of the role of IL-23/IL-17 may suggest a preventive strategy acting on this axis. A better
characterization of mucosal immunity and its role in the pathogenesis of RA is an open issue and
should be a priority in the research agenda.
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Figure 2. Interplay between mucosal events. At oral and lung levels, under the stimulus of periodontal
pathogens or environmental factors, there is a production of citrullinated proteins, directly or through
NETosis, and consequently ACPA production. At the gut level, dysbiosis induces the imbalance
between Th17 and Treg. Th17 may migrate to the lung, contributing to iBALT formation, and at the
systemic level, where, through the IL-23/IL17-axis, the abnormal glycosylation and the acquisition of
ACPA pro-inflammatory activity are triggered. Inflammatory cells and ACPAs can at last induce the
onset of arthritis. Cit-p: citrullinated proteins; iBALT: inducible bronchus associated lymphatic tissue;
IL-: Interleukin-.
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